Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | EU-OPENSCREEN | TEST |
Test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
info here |
Partnerships |
Events |
Jobs |
The Division of Signal Transduction TherapyA vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT) which was established in 1998. This division operates as a unique collaboration between scientists in the MRC-PPU (all PIs including Ronald Hay FRS Honorary PI of... View all Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
